☆ 4.7 Article

European Committee for Treatment and Research in Multiple Sclerosis and European Academy of Neurology consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs

EUROPEAN JOURNAL OF NEUROLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Clinical Neurology

Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations

Marton Konig et al.

Summary: This study aimed to characterize humoral immunity after mRNA-COVID-19 vaccination in people with multiple sclerosis (pwMS). The study found that patients treated with fingolimod or rituximab had reduced humoral immunity. It is important to carefully time the vaccinations for patients treated with rituximab.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2023)

Add to Collection

Article Clinical Neurology

B Cell Depletion and SARS-CoV-2 Vaccine Responses in Neuroimmunologic Patients

Barbara Kornek et al.

Summary: The study found that patients on anti-CD20 therapy had lower rates of SARS-CoV-2-specific antibodies compared to controls, but antibody levels were lower in patients without detectable B cells. In contrast, B-cell depleted patients showed a more pronounced T-cell response to the Wuhan strain and Delta variant compared to nondepleted patients.

ANNALS OF NEUROLOGY (2022)

Add to Collection

Article Clinical Neurology

COVID-19 Vaccine Response in People with Multiple Sclerosis

Emma C. Tallantyre et al.

Summary: The study found that some disease modifying therapies are associated with attenuated serological responses to SARS-CoV-2 vaccination in people with multiple sclerosis, including anti-CD20 monoclonal antibodies and fingolimod treatment. Additionally, vaccine type and treatment duration also impact vaccine response.

ANNALS OF NEUROLOGY (2022)

Add to Collection

Article Clinical Neurology

Humoral- and T-Cell Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies

Carla Tortorella et al.

Summary: This study evaluated the immune-specific response after full SARS-CoV-2 vaccination in patients with multiple sclerosis (MS) treated with different disease-modifying drugs. The results showed that mRNA vaccines induced both humoral and cell-mediated specific immune responses against viral spike proteins in the majority of patients with MS. These findings have important implications for promoting vaccination in all MS patients.

NEUROLOGY (2022)

Add to Collection

Article Clinical Neurology

Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies

Fioravante Capone et al.

Summary: This study evaluated the immunogenicity and safety of mRNA COVID-19 vaccines in MS patients treated with different DMTs. Patients treated with first-line DMTs all developed a measurable humoral response after vaccination, while those treated with ocrelizumab and fingolimod had significantly lower IgG levels in some cases.

NEUROTHERAPEUTICS (2022)

Add to Collection

Letter Clinical Neurology

First manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine

Joachim Havla et al.

JOURNAL OF NEUROLOGY (2022)

Add to Collection

Letter Clinical Neurology

mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis

Massimiliano Di Filippo et al.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2022)

Add to Collection

Review Clinical Neurology

Vaccination and immunotherapies in neuroimmunological diseases

Alexander Winkelmann et al.

Summary: Neuroimmunological diseases and their treatment can affect immune responses to vaccinations, so careful selection and management of vaccines are necessary during immunotherapy to reduce the risk of infection and protect patients from disease.

NATURE REVIEWS NEUROLOGY (2022)

Add to Collection

Letter Clinical Neurology

Varicella zoster virus and influenza vaccine antibody titres in patients from MAGNIFY-MS who were treated with cladribine tablets for highly active relapsing multiple sclerosis

Klaus Schmierer et al.

MULTIPLE SCLEROSIS JOURNAL (2022)

Add to Collection

Review Clinical Neurology

Multiple sclerosis relapse after COVID-19 vaccination: A case report-based systematic review

Fardin Nabizadeh et al.

Summary: Some patients with multiple sclerosis (MS) may experience relapses after receiving the COVID-19 vaccine. Although COVID-19 infection itself can also trigger relapses, the benefits of vaccination outweigh the risks, and vaccination against COVID-19 should be encouraged in MS patients.

JOURNAL OF CLINICAL NEUROSCIENCE (2022)

Add to Collection

Article Clinical Neurology

Recommendations for vaccination in patients with multiple sclerosis who are eligible for immunosuppressive therapies: Spanish consensus statement

S. Otero-Romero et al.

Summary: The recent development of highly effective treatments for multiple sclerosis (MS) necessitates the development of prevention and risk minimisation strategies due to the potential risk of infectious complications. Vaccination is crucial in managing MS patients receiving highly effective immunosuppressive treatments. The consensus statement provides recommendations and practical scenarios for the vaccination of adult patients with MS.

NEUROLOGIA (2021)

Add to Collection

Article Rheumatology

Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study

Matthias B. Moor et al.

Summary: The study investigated immune responses to SARS-CoV-2 mRNA vaccines in patients receiving CD20-targeted B-cell-depleting therapies. Results showed blunted immune responses in these patients, indicating potential challenges in vaccination strategies for this population.

LANCET RHEUMATOLOGY (2021)

Add to Collection

Review Clinical Neurology

Vaccinations in patients with multiple sclerosis: A Delphi consensus statement

Agostino Riva et al.

Summary: Recommendations for vaccinations in patients with multiple sclerosis include considering risks and benefits carefully, and there is an urgent need for more research to guide evidence-based decision making.

MULTIPLE SCLEROSIS JOURNAL (2021)

Add to Collection

Article Multidisciplinary Sciences

Incidence, risk factors and impact of seasonal influenza in pregnancy: A national cohort study

Nicola Vousden et al.

Summary: This study described the characteristics and outcomes of pregnant women hospitalized with seasonal influenza, showing that women with influenza during pregnancy are more likely to have pregnancy complications, increased risk of hospitalization and cesarean birth, and their babies are more likely to be admitted to neonatal intensive care.

PLOS ONE (2021)

Add to Collection

Article Immunology

Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study

Anat Achiron et al.

Summary: The study found that most multiple sclerosis (MS) patients who were either untreated or treated with certain drugs exhibited a protective immune response following PfizerBNT162b2 vaccination. In contrast, patients treated with other medications showed a weaker immune response.

JOURNAL OF NEUROIMMUNOLOGY (2021)

Add to Collection

Editorial Material Clinical Neurology

T cells step up after SARS-CoV-2 vaccination with B cell depletion

Thomas Berger et al.

Summary: Detailed immunological analysis in a new study sheds light on the immune responses after SARS-CoV-2 vaccination in individuals receiving B cell-depleting therapy for multiple sclerosis. While the findings have implications for clinical practice, more questions remain about SARS-CoV-2 vaccination and immunosuppression.

NATURE REVIEWS NEUROLOGY (2021)

Add to Collection

Review Medicine, General & Internal

Vaccines for older adults

Anthony L. Cunningham et al.

Summary: The global population aged 65 and older is increasing rapidly, with infections in this age group causing substantial morbidity and mortality. Improvements in vaccines for older people, including the addition of novel adjuvants and increasing antigen concentration, have been made to combat vaccine preventable diseases of aging.

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Article Clinical Neurology

T-cell responses to SARS-CoV-2 in multiple sclerosis patients treated with ocrelizumab healed from COVID-19 with absent or low anti-spike antibody titers

Marco Iannetta et al.

Summary: In patients with multiple sclerosis receiving ocrelizumab treatment, specific T-cell responses to SARS-CoV-2 can still be detected, even in the absence of antibodies. This finding represents a useful tool for improving diagnostic approaches and accurately assessing immune responses in SARS-CoV-2 infection.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2021)

Add to Collection

Article Immunology

Effect of Different Disease-Modifying Therapies on Humoral Response to BNT162b2 Vaccine in Sardinian Multiple Sclerosis Patients

Maristella Pitzalis et al.

Summary: The study found that different DMTs may significantly impact the humoral immune response of MS patients following COVID-19 vaccination. Factors such as age, sex, and smoking status of patients may also influence the immune response.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy

Sachin P. Gadani et al.

Summary: This study found robust T cell responses in individuals with multiple sclerosis on anti-CD20 therapies despite a reduced humoral response to SARS-CoV-2 vaccination. Follow-up studies are needed to determine if this translates to protection against COVID-19 infection.

EBIOMEDICINE (2021)

Add to Collection

Article Immunology

Humoral Immune Response after the Third SARS-CoV-2 mRNA Vaccination in CD20 Depleted People with Multiple Sclerosis

Lutz Achtnichts et al.

Summary: Research indicates that individuals with MS who undergo CD20 depletion therapy have limited humoral immune response even after receiving a third dose of mRNA vaccine. Further investigation is needed to determine if T-cell responses can provide sufficient protection against CoV-2 infections in these individuals.

VACCINES (2021)

Add to Collection

Article Clinical Neurology

Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus

Diego Centonze et al.

Summary: COVID-19 emerged in Wuhan, China in December 2019 and quickly spread globally, with over 132 million cases and 2.8 million deaths recorded to date. A massive vaccination campaign has been initiated worldwide since the end of 2020, although there are concerns among neurologists about the safety and efficacy of vaccination in multiple sclerosis patients on immunomodulatory or immunosuppressive therapies.

JOURNAL OF NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

Multiple sclerosis: Is there a risk of worsening after yellow fever vaccination?

Caroline Papeix et al.

Summary: The study conducted on the French national cohort found that the yellow fever vaccine (YFV) does not worsen the course of relapsing-remitting multiple sclerosis (RR-MS).

MULTIPLE SCLEROSIS JOURNAL (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy

Sokratis A. Apostolidis et al.

Summary: Patients with multiple sclerosis on anti-CD20 monotherapy exhibit significantly reduced SARS-CoV-2-specific antibodies and memory B cells, while CD4(+) and CD8(+) T cells are robustly activated compared to healthy controls after receiving BNT162b2 or mRNA-1273 mRNA vaccination.

NATURE MEDICINE (2021)

Add to Collection

Letter Clinical Neurology

Association of Disease-Modifying Treatment and Anti-CD20 Infusion Timing With Humoral Response to 2 SARS-CoV-2 Vaccines in Patients With Multiple Sclerosis

Giulio Disanto et al.

JAMA NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

Humoral and T-Cell Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Ocrelizumab

Livnat Brill et al.

Summary: Patients with MS treated with ocrelizumab showed comparable SARS-CoV-2-specific T-cell responses with healthy controls but lower antibody response following vaccination. This study provides reassurance regarding the potential role of T cells in protection from severe disease and will aid in the development of consensus guidelines for MS treatment during the COVID-19 pandemic.

JAMA NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

Rabies vaccination and multiple sclerosis relapse: A retrospective cohort study

Angela Huttner et al.

Summary: In this cohort, rabies vaccination was not associated with clinical MS relapse. Larger, prospective studies are needed to confirm these results.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2021)

Add to Collection

Article Medicine, General & Internal

Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies

Maria Pia Sormani et al.

Summary: This study found that anti-CD20 treatment and fingolimod in MS patients led to reduced humoral response to mRNA vaccines. mRNA-1273 vaccine resulted in significantly higher antibody levels compared to BNT162b2, suggesting it may be preferred for patients under certain treatments.

EBIOMEDICINE (2021)

Add to Collection

Review Immunology

Multiple Sclerosis, Disease-Modifying Therapies and COVID-19: A Systematic Review on Immune Response and Vaccination Recommendations

Veronica Cabreira et al.

Summary: Most MS patients receiving DMTs do not have a higher risk of severe COVID-19, but factors like age, comorbidities, and disability can significantly impact outcomes. While most DMTs have minimal influence on COVID-19, therapies causing severe lymphopenia and hypogammaglobulinemia, like anti-CD20 therapies, may lead to increased hospitalization, worse outcomes, and higher reinfection risk.

VACCINES (2021)

Add to Collection

Review Hematology

Vaccine response following anti-CD20 therapy: a systematic review and meta-analysis of 905 patients

Abi Vijenthira et al.

Summary: The study found that patients receiving anti-CD20 therapy have poor responses to all types of vaccines, especially during treatment and at least 6 months post-treatment, with significantly lower SC rates compared to healthy and disease control groups. As time progresses, response to vaccination gradually improves, but even 12 months post-therapy, it may not reach the level of healthy controls.

BLOOD ADVANCES (2021)

Add to Collection

Article Clinical Neurology

Humoral immune response and lymphocyte levels after complete vaccination against COVID-19 in a cohort of multiple sclerosis patients treated with cladribine tablets

Christoph Grothe et al.

Summary: This study investigated the humoral response to COVID-19 vaccination in MS patients treated with cladribine tablets, finding that treatment with cladribine tablets did not impair humoral response to COVID-19 vaccination.

JOURNAL OF CENTRAL NERVOUS SYSTEM DISEASE (2021)

Add to Collection

Article Clinical Neurology

Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies

Anat Achiron et al.

Summary: The study found that after receiving the COVID-19 vaccine, MS patients who were either untreated or treated with cladribine showed a high level of protective humoral immunity, similar to healthy subjects. However, only a small percentage of MS patients treated with ocrelizumab and fingolimod developed a humoral immune response.

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2021)

Add to Collection

Review Rheumatology

2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases

Victoria Furer et al.

ANNALS OF THE RHEUMATIC DISEASES (2020)

Add to Collection

Article Clinical Neurology

Tick-borne encephalitis vaccination in multiple sclerosis A prospective, multicenter study

Alexander Winkelmann et al.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2020)

Add to Collection

Article Biotechnology & Applied Microbiology

Why vaccines matter: understanding the broader health, economic, and child development benefits of routine vaccination

Arindam Nandi et al.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2020)

Add to Collection

Article Clinical Neurology

Risk of MS relapse after yellow fever vaccination A self-controlled case series

Angela Huttner et al.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2020)

Add to Collection

Article Clinical Neurology

Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis The VELOCE study

Amit Bar-Or et al.

NEUROLOGY (2020)

Add to Collection

Review Clinical Neurology

Effects of MS disease-modifying therapies on responses to vaccinations: A review

John Robert Ciotti et al.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)

Add to Collection

Review Clinical Neurology

Protecting people with multiple sclerosis through vaccination

Saul Reyes et al.

PRACTICAL NEUROLOGY (2020)

Add to Collection

Article Neurosciences

Immunogenicity and predictors of response to a single dose trivalent seasonal influenza vaccine in multiple sclerosis patients receiving disease-modifying therapies

Christoph Metze et al.

CNS NEUROSCIENCE & THERAPEUTICS (2019)

Add to Collection

Article Infectious Diseases

Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7)

Catherine Cordonnier et al.

LANCET INFECTIOUS DISEASES (2019)

Add to Collection

Review Clinical Neurology

Epidemiology and treatment of multiple sclerosis in elderly populations

Caila B. Vaughn et al.

NATURE REVIEWS NEUROLOGY (2019)

Add to Collection

Review Clinical Neurology

Immunization and multiple sclerosis: Recommendations from the French multiple sclerosis society

Christine Lebrun et al.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2019)

Add to Collection

Article Infectious Diseases

Pregnancy as a risk factor for severe influenza infection: an individual participant data meta-analysis

Dominik Mertz et al.

BMC INFECTIOUS DISEASES (2019)

Add to Collection

Article Clinical Neurology

Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology

Mauricio F. Farez et al.

NEUROLOGY (2019)

Add to Collection

Review Medicine, General & Internal

Vaccines for International Travel

David O. Freedman et al.

MAYO CLINIC PROCEEDINGS (2019)

Add to Collection

Article Multidisciplinary Sciences

Anti-CD20 therapy depletes activated myelin-specific CD8+ T cells in multiple sclerosis

Joseph J. Sabatino et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)

Add to Collection

Article Geriatrics & Gerontology

Vaccinations in Older Adults

Megan Burke et al.

CLINICS IN GERIATRIC MEDICINE (2018)

Add to Collection

Article Clinical Neurology

Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy

H. K. Olberg et al.

EUROPEAN JOURNAL OF NEUROLOGY (2018)

Add to Collection

Article Obstetrics & Gynecology

Influenza Vaccination, Pregnancy Safety, and Risk of Early Pregnancy Loss

Rhoda S. Sperling et al.

OBSTETRICS AND GYNECOLOGY (2018)

Add to Collection

Editorial Material Pediatrics

Human papillomavirus vaccine for children and adolescents

Marina I. Salvadori

PAEDIATRICS & CHILD HEALTH (2018)

Add to Collection

Article Clinical Neurology

Immune response to vaccines is maintained in patients treated with dimethyl fumarate

Christian von Hehn et al.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2018)

Add to Collection

Article Clinical Neurology

Impact of siponimod on vaccination response in a randomized, placebo-controlled study

Mike Ufer et al.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2017)

Add to Collection

Article Education, Scientific Disciplines

Is There a Consensus on Consensus Methodology? Descriptions and Recommendations for Future Consensus Research

Jane Waggoner et al.

ACADEMIC MEDICINE (2016)

Add to Collection

Article Pediatrics

Characteristics of Children and Adolescents With Multiple Sclerosis

Anita L. Belman et al.

PEDIATRICS (2016)

Add to Collection

Review Biotechnology & Applied Microbiology

Pertussis vaccination in pregnancy

C. Mary Healy

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2016)

Add to Collection

Article Clinical Neurology

Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis

Ludwig Kappos et al.

NEUROLOGY (2015)

Add to Collection

Article Obstetrics & Gynecology

Vaccinations for Pregnant Women

Geeta K. Swamy et al.

OBSTETRICS AND GYNECOLOGY (2015)

Add to Collection

Article Clinical Neurology

Randomized study of teriflunomide effects on immune responses to neoantigen and recall antigens

Amit Bar-Or et al.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2015)

Add to Collection

Article Immunology

2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host

Lorry G. Rubin et al.

CLINICAL INFECTIOUS DISEASES (2014)

Add to Collection

Article Clinical Neurology

Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis

Michael Kaufman et al.

JOURNAL OF THE NEUROLOGICAL SCIENCES (2014)

Add to Collection

Article Clinical Neurology

Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: an explorative study

Henning K. Olberg et al.

MULTIPLE SCLEROSIS JOURNAL (2014)

Add to Collection

Article Clinical Neurology

Effects of Bacille Calmette-Guerin after the first demyelinating event in the CNS

Giovanni Ristori et al.

NEUROLOGY (2014)

Add to Collection

Article Clinical Neurology

AVIDITY OF VACCINE-INDUCED INFLUENZA IgG FAILS TO INCREASE IN FINGOLIMOD-TREATED PATIENTS WITH MS

Matthias Mehling et al.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2014)

Add to Collection

Article Clinical Neurology

Reduced antibody formation after influenza vaccination in patients with neuromyelitis optica spectrum disorder treated with rituximab

W. Kim et al.

EUROPEAN JOURNAL OF NEUROLOGY (2013)

Add to Collection

Article Clinical Neurology

Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis

Amit Bar-Or et al.

NEUROLOGY (2013)

Add to Collection

Article Clinical Neurology

Immune competence after alemtuzumab treatment of multiple sclerosis

Claire L. McCarthy et al.

NEUROLOGY (2013)

Add to Collection

Article Multidisciplinary Sciences

Preserved Antigen-Specific Immune Response in Patients with Multiple Sclerosis Responding to IFNβ-Therapy

Matthias Mehling et al.

PLOS ONE (2013)

Add to Collection

Review Nursing

Parents, adolescents, children and the human papillomavirus vaccine: a review

T. Walhart

INTERNATIONAL NURSING REVIEW (2012)

Add to Collection

Article Pharmacology & Pharmacy

Pharmacodynamic Effects of Steady-State Fingolimod on Antibody Response in Healthy Volunteers: A 4-Week, Randomized, Placebo-Controlled, Parallel-Group, Multiple-Dose Study

Craig Boulton et al.

JOURNAL OF CLINICAL PHARMACOLOGY (2012)

Add to Collection

Article Clinical Neurology

Seasonal and H1N1v influenza vaccines in MS: Safety and compliance

Eitan Auriel et al.

JOURNAL OF THE NEUROLOGICAL SCIENCES (2012)

Add to Collection

Letter Clinical Neurology

H1N1 vaccination does not increase risk of relapse in multiple sclerosis: a self-controlled case-series study

Mauricio F. Farez et al.

MULTIPLE SCLEROSIS JOURNAL (2012)

Add to Collection

Review Clinical Neurology

Vaccination against infection in patients with multiple sclerosis

Micha Loebermann et al.

NATURE REVIEWS NEUROLOGY (2012)

Add to Collection

Article Clinical Neurology

Humoral immune response to influenza vaccine in natalizumab-treated MS patients

Mattias Vagberg et al.

NEUROLOGICAL RESEARCH (2012)

Add to Collection

Article Clinical Neurology

Antigen-Specific Adaptive Immune Responses in Fingolimod-Treated Multiple Sclerosis Patients

Matthias Mehling et al.

ANNALS OF NEUROLOGY (2011)

Add to Collection

Article Clinical Neurology

Yellow Fever Vaccination and Increased Relapse Rate in Travelers With Multiple Sclerosis

Mauricio F. Farez et al.

ARCHIVES OF NEUROLOGY (2011)

Add to Collection

Letter Clinical Neurology

Relapse risk in patients with multiple sclerosis after H1N1 vaccination, with or without seasonal influenza vaccination

Nuala McNicholas et al.

JOURNAL OF NEUROLOGY (2011)

Add to Collection

Article Rheumatology

Immunization Responses in Rheumatoid Arthritis Patients Treated With Rituximab Results From a Controlled Clinical Trial

Clifton O. Bingham et al.

ARTHRITIS AND RHEUMATISM (2010)

Add to Collection

Review Immunology

Correlates of Protection Induced by Vaccination

Stanley A. Plotkin

CLINICAL AND VACCINE IMMUNOLOGY (2010)

Add to Collection

Article Virology

Protective role of beta interferon in host defense against influenza A virus

Iris Koerner et al.

JOURNAL OF VIROLOGY (2007)

Add to Collection

Article Clinical Neurology

Immune response to influenza vaccine is maintained in patients with multiple sclerosis receiving interferon beta-1a

SR Schwid et al.

NEUROLOGY (2005)

Add to Collection

Article Immunology

Controlled trial of tick-borne encephalitis vaccination in patients with multiple sclerosis

U Baumhackl et al.

VACCINE (2003)

Add to Collection

Article Clinical Neurology

Immunization and MS - A summary of published evidence and recommendations

OT Rutschmann et al.

NEUROLOGY (2002)

Add to Collection

Article Clinical Neurology

Anti-viral properties of interferon beta treatment in patients with multiple sclerosis

J Hong et al.

MULTIPLE SCLEROSIS JOURNAL (2002)

Add to Collection

Article Clinical Neurology

Influenza vaccination in MS - Absence of T-cell response against white matter proteins

NF Moriabadi et al.

NEUROLOGY (2001)

Add to Collection

Article Medicine, General & Internal

Vaccinations and the risk of relapse in multiple sclerosis

C Confavreux et al.

NEW ENGLAND JOURNAL OF MEDICINE (2001)

Add to Collection

© Peeref 2019-2024. All rights reserved.